Sonnerie VC has invested in BMI OrganBank, joining the company’s growing community of investors alongside Mid Atlantic Bio Angels. It is exactly the kind of company we are built to back: operator- and clinician-driven, working in a deeply regulated market, on a problem where success means more lives saved.
BMI OrganBank develops organ preservation and assessment systems that improve how donor organs are evaluated, preserved, and transported within the transplant ecosystem. Beginning with the kidney, the company is advancing room-temperature perfusion designed to maintain physiological activity, extend the preservation window, and generate the data that supports more informed clinical decisions.
Every year, viable organs are lost to the limits of how we preserve and assess them. That is a signal worth amplifying.
The company’s technology emerged from serious science, its research facilities sit within the Innovation Accelerator at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina, and in Research Triangle Park, and it is led by a team pairing clinical insight with the discipline to build in a regulated category. That combination of breakthrough science, a clear clinical destination, and an operator-led team is precisely our thesis.
We’re grateful to the BMI OrganBank team for a thoughtful diligence process and proud to support the company as it advances toward its next phase. We look forward to working alongside its investors, clinicians, and partners, and to helping, where we can, on the path from breakthrough science to clinical and commercial impact.
For more on BMI OrganBank’s technology and team, visit bmiorganbank.com.